Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
Make way for MiniMed! Medtronic's diabetes division has filed the necessary paperwork to go public. The company hopes to be traded on Nasdaq under the symbol MMED.
The Pennsylvania-based drug distributor announced it would be buying OneOncology, a physician-led specialty service group in which it already owned a minority stake. The company said the acquisition will complement its "pharmaceutical-centric strategy."
Paxton says the “woke” EHR giant is intentionally making it harder for patients and families to access historical medical data, violating state law. Epic denies the allegation.
Mark Cuban's startup Cost Plus Drugs and insurer Humana are said to be working on a deal that would allow Medicare Advantage patients to buy drugs directly from manufacturers. The terms of the agreement—which Forbes reports is in its early stages—are still unknown.
It’s been years since AI proponents started promising big returns on healthcare providers’ investments in the technology. The results have yet to catch up with the pitches. What’s the holdup?
The new 7,000-square-meter plant is located in France and will begin production of thorium-228, necessary for the development of isotopes used in cancer treatments.
Working with Medicare Advantage insurance plans is like playing poker in the Wild West. And it’s gotten a lot harder to win since the cowboys started using AI.